PlainPharmaWatch

CMS Open Payments · Program Year 2024

Reprise Biomedical, Inc.

Reprise Biomedical, Inc. reported $116,966.85 in payments to 1,101 physicians and teaching hospitals across 1,101 transactions.

See the rankings → How this is sourced
$117.0K
Total payments
1,101
Transactions
1,101
Recipients
+$55.5K
General Payments vs PY2023

Reprise Biomedical, Inc. reported $116,966.85 in payments to 1,101 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #1146 of 1,925 reporting manufacturers (0.0% of all US industry payments), averaging $106.24 per recipient across 4 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

Reprise Biomedical, Inc. pairs below-median payment volume with a broadly spread payment pattern across many recipients.

#1146
of 1,925 companies
0.0%
of all US industry payments
0.2%
paid to its single top recipient
4
payment categories

Release-over-release change

General Payments changed from PY2023 to PY2024

Reprise Biomedical, Inc.'s CMS-reported General Payments increased by $55.5K (+90.3%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.

CMS source labels for this exact identifier: PY2022: REPRISE BIOMEDICAL, INC.PY2023: REPRISE BIOMEDICAL, INC.PY2024: Reprise Biomedical, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$61.5KPY2024$117.0K
PY2023
$61,462.40
PY2024
$116,966.85

How Reprise Biomedical, Inc. ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

Reprise Biomedical, Inc.'s total vs. every reporting company

CMS Open Payments, Program Year 2024

$116,967 41st percentile higher than 41% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). Below this entry. $78,003–$242,294: 295 reporting companies (15%). This entry sits in this band. $242,294–$752,621: 270 reporting companies (14%). Above this entry. $752,621–$2,337,813: 263 reporting companies (14%). Above this entry. $2,337,813–$7,261,783: 200 reporting companies (10%). Above this entry. $7,261,783–$22,556,757: 133 reporting companies (7%). Above this entry. $22,556,757–$70,066,439: 45 reporting companies (2%). Above this entry. $70,066,439–$217,642,369: 26 reporting companies (1%). Above this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for Reprise Biomedical, Inc.

Reprise Biomedical, Inc. ranks #1146 out of 1,925 companies in the CMS Open Payments database for Program Year 2024, a comparatively small 0.0% slice of all industry payments reported nationwide for the year. The underlying total is $116,966.85 across 1,101 transactions to 1,101 physicians and teaching hospitals - $106.24 per transaction and $106.24 per recipient on average.

"Consulting Fee" leads the 4-category general-payment breakdown below at $80.3K (68.7% of the company's reported total, 33 transactions) - see our methodology for how research and ownership payments are reported separately.

General Payment Breakdown by Type

Reprise Biomedical, Inc. made 4 types of general payments. "Consulting Fee" is the largest category at $80.3K, 68.7% of the company's reported total.

How Reprise Biomedical, Inc. divides its payments

How the reported total splits across payment categories

1. Consulting Fee$80.3K2. Food and Beverage$32.9K3. Travel and Lodging$3.7K4. Compensation for Services…$7.05
Payment Type Amount Transactions
Consulting Fee $80.3K 33
Food and Beverage $32.9K 1,058
Travel and Lodging $3.7K 9
Compensation for Services Other Than Consulting $7.05 1

Recipient Concentration in General Payments

The five largest recipient relationships account for $81,678.96 (69.8%) of $116,966.85 in this company's General Payments records across 861 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Reprise Biomedical, Inc.

The five named recipients with the highest reported General Payments from this company

Robert Snyder$24.0KAmy Couch$23.2KWalaya Methodius-Rayford$16.7KRaymond Abdo$11.9KAli Saberi$5.8K
  1. 1

    Robert Snyder

    $24,042.42 across 7 reported transactions

  2. 2

    Amy Couch

    $23,237.85 across 14 reported transactions

  3. 3

    Walaya Methodius-Rayford

    $16,668.82 across 10 reported transactions

  4. 4

    Raymond Abdo

    $11,934.10 across 19 reported transactions

  5. 5

    Ali Saberi

    $5,795.77 across 7 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $106.24. Average per recipient: $106.24.

Total Amount

$116,966.85

Avg per Transaction

$106.24

Avg per Recipient

$106.24

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

Reprise Biomedical, Inc. Share

0.0%

#1146 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to Reprise Biomedical, Inc.

Caldera Medical, Inc

$117.1K 1,085 recipients

Linde Gas & Equipment Inc.

$116.7K 348 recipients

Ferring International Pharmascience Center US

$116.6K 3 recipients

Jan Medical Inc.

$117.5K 6 recipients

Brixton Biosciences, Inc.

$117.6K 72 recipients

Forte Bio-Pharma LLC

$118.4K 5,751 recipients

Frequently Asked Questions

How much did Reprise Biomedical, Inc. pay to physicians and hospitals in 2024? ▾
In Program Year 2024, CMS Open Payments recorded $116,966.85 from Reprise Biomedical, Inc. to physicians and hospitals across 1,101 transactions - 0.0% of all industry payments reported that year.
How many physicians received payments from Reprise Biomedical, Inc.? ▾
Reprise Biomedical, Inc. made payments to 1,101 physicians and teaching hospitals in 2024. The average payment per recipient was $106.24.
What types of payments did Reprise Biomedical, Inc. make? ▾
4 categories of general payment make up Reprise Biomedical, Inc.'s reported activity, including consulting, meals, travel, and similar types. The largest general-payment category was "Consulting Fee" at $80.3K, representing 68.7% of the company's reported total.
How does Reprise Biomedical, Inc. rank among pharmaceutical companies? ▾
By total payment amount, Reprise Biomedical, Inc. sits at #1146 of 1,925 companies in the CMS Open Payments database for 2024.
What is the average payment size from Reprise Biomedical, Inc.? ▾
Reprise Biomedical, Inc.'s 1,101 transactions to 1,101 recipients in 2024 averaged $106.24 per transaction.
Where does the payment data for Reprise Biomedical, Inc. come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Reprise Biomedical, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.